GCB-27b
GCB-27b is an immunostimulant that binds to CD1d. GCB-27b forms a stable and long-lasting complex with CD1d, which is presented to the TCR of NKT cells to drive immune responses. GCB-27b induces a Th1-skewed immune response in *Mus musculus*, resulting in high expression of IFN?γ with restricted IL-4 levels. GCB-27b is applicable to research related to lung metastasis of melanoma.
For research use only. We do not sell to patients.
- Formula: C52H95NO10
- Molecular Weight:894.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
GCB-27b (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with no observed cytotoxicity[1].
GCB-27b (100 nM; 2-24 h) forms more stable and sustained complexes with CD1d on mouse BMDCs in vitro, with enhanced surface presentation relative to αGalCer at 12, 18, and 24 h postincubation[1].
GCB-27b (24 h) potently induces Th1-biased activation of human PBMC-derived NKT cells in vitro, with a 2-fold higher frequency of IFN-γ+ cells relative to αGalCer[1].
GCB-27b has higher computed binding affinity for both human and murine CD1d than αGalCer, with a docking score of 20 for both, due to optimized hydrophobic interactions in the CD1d A' pocket[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GCB-27b (2.33 nmol per mouse; i.p.; single dose) potently activates splenic DCs (via increased CD80 and CD86 expression) and NK cells (via elevated IFN?γ production) in C57BL/6 mice, demonstrating robust innate immune stimulation[1].
GCB-27b (0.58 nmol per mouse; i.p.; single dose) reduces B16?F10 melanoma lung metastatic nodule counts by 88% relative to αGalCer in C57BL/6 mice, driven by a potent Th1-biased cytokine response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (n=5)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced a 10.5-fold increase in serum IFN-γ levels (measured at 24 h postinjection) relative to αGalCer.
Showed IL-4 levels (measured at 2 h postinjection) comparable to those induced by αGalCer.
Demonstrated IL-4 levels peaked at 2 h then declined, while IFN-γ levels peaked at 24 h then declined, consistent with strong Th1-biased activity.
-
Animal Model:C57BL/6 (n=3)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced significantly increased mean fluorescence intensity (MFI) of CD80 and CD86 on CD11c+ dendritic cells (DCs) relative to αGalCer.
Elevated the proportion of IFN-γ+ NK cells in the spleen to 17.6%, which is significantly higher than the proportion induced by αGalCer.
-
Animal Model:C57BL/6 (n=6; melanoma lung metastasis model)[1]
-
Dosage:0.58 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced significantly elevated serum IFN-γ levels (measured at 24 h postinjection) relative to αGalCer, with IL-4 levels (measured at 2 h postinjection) comparable to those induced by αGalCer.
Reduced lung metastatic nodule counts by 88% relative to the αGalCer-treated group, with near-complete inhibition of lung metastasis confirmed by H&E staining.
Chemical Information
-
Molecular Weight 894.31
-
Formula C52H95NO10
-
SMILES
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCCC)CCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)